Claim your FREE Gift & Newsletter. Just enter your... E-MAIL ADDRESS

First Name

Then

Don't worry -- your e-mail address is totally secure.
I promise to use it only to send you Prospering With Arthritis.


Get Back Into the Swing of Things!

Get the Best Bang for Your Buck... Click Here

If  this website was helpful, 
Please
Click below to... 
   


Joint Pain Forum – News you can use!

back to Arthritis News Archives


NASONEX Earns the Arthritis Foundation Ease-of-Use Commendation




March 12, 2007

By DrugNewswire

The NASONEX(R) (mometasone furoate monohydrate) Nasal Spray 50mcg* delivery device is the first nasal allergy spray acknowledged by the Arthritis Foundation as easy-to-use for people with arthritis

KENILWORTH, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Schering-Plough today announced that the device used to deliver NASONEX(R) (mometasone furoate monohydrate) nasal spray for the treatment of nasal allergy symptoms has received the Arthritis Foundation's Ease-of-Use Commendation. The commendation recognizes products that provide accessibility or ease-of-use for people with arthritis as determined by an independent lab experienced in the design and evaluation of products and individuals with various forms of the chronic illness.

"Products that receive the Ease-of-Use Commendation have been shown to make everyday tasks, like administering a medication, easy and comfortable for people with arthritis," said Mary Norman, Arthritis Foundation group vice president of strategic marketing alliances.

The Arthritis Foundation created the Ease-of-Use Commendation Program to encourage manufacturers to design user-friendly products and packaging that could be recommended to the nearly 46 million Americans who are affected by some form of arthritis. The NASONEX delivery device is the first nasal allergy spray to have the Ease-of-Use Commendation from the Foundation.





An estimated 37 million Americans suffer from the symptoms of seasonal and perennial allergies. A nasal-inhaled steroid, such as NASONEX, is a recommended first-line therapy for all nasal symptoms of allergic rhinitis. NASONEX is the only once-daily prescription intranasal corticosteroid approved to help prevent seasonal nasal allergy symptoms in adults and children 12 years of age and older when NASONEX is started 2 to 4 weeks prior to allergy season. NASONEX is also the only intranasal corticosteroid approved to treat nasal allergy symptoms, including nasal congestion, in patients as young as 2 years of age.

NASONEX Ease-of-Use Patient Survey

A separate consumer survey of NASONEX users also demonstrates that the applicator is easy for patients to use. In a survey of more than 1,500 NASONEX users and caregivers of young children who use NASONEX, 98 percent of those surveyed found the NASONEX applicator easy to use. NASONEX users also report that the mist from the NASONEX applicator is easy to administer and that the NASONEX applicator is easy to pump and press.

Users also indicate that the NASONEX nasal spray applicator:

-- Fits comfortably in the nostril (96 percent of all users surveyed)
-- Fits comfortably in the hand (96 percent of all users surveyed)
-- Is appropriately sized to administer the medicine (95 percent of all users surveyed)
-- Is comfortable to hold while administering a dose or mist in the nose (94 percent of all users surveyed)

The survey was performed in November 2006 to evaluate whether patients find the NASONEX nasal spray applicator easy and comfortable to use and included a sample of general NASONEX users (n=1,126), pediatric NASONEX users (n=506), elderly NASONEX users (n=355) and arthritic NASONEX users (n=562). The sample was recruited from the Synovate interactive online panel and purchased sample.

back to Arthritis News Archives














Bookmark This Page...
AddThis Social Bookmark Button
                                                

MEMBERS AREA | Site Map | CONTACT US
Privacy | Terms


About Us